Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    16568084 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Unknown  Dasatinib in Relapsed or Refractory Non-Hodgkin's Lymphoma
Condition: Non-Hodgkin's Lymphoma
Intervention: Drug: Dasatinib

Indicates status has not been verified in more than two years